William Blair Issues Negative Forecast for Moderna Earnings

Moderna, Inc. (NASDAQ:MRNA) – William Blair lowered their Q3 2025 EPS estimates for Moderna in a research note issued on Thursday, October 23rd. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($2.54) for the quarter, down from their previous estimate of ($2.26). The consensus estimate for Moderna’s current full-year earnings is ($9.61) per share. William Blair also issued estimates for Moderna’s Q4 2025 earnings at ($3.34) EPS, FY2025 earnings at ($10.53) EPS, Q1 2026 earnings at ($2.99) EPS, Q2 2026 earnings at ($2.82) EPS, Q3 2026 earnings at ($1.93) EPS, Q4 2026 earnings at ($1.56) EPS and FY2026 earnings at ($9.30) EPS.

MRNA has been the subject of several other research reports. JPMorgan Chase & Co. dropped their price target on shares of Moderna from $26.00 to $25.00 and set an “underweight” rating for the company in a research report on Thursday, October 23rd. Evercore ISI set a $32.00 price target on shares of Moderna in a research report on Friday, August 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Moderna in a research report on Wednesday, October 8th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Monday, October 20th. Finally, UBS Group dropped their price target on shares of Moderna from $70.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $36.86.

Moderna Stock Performance

NASDAQ MRNA opened at $26.66 on Monday. The firm has a 50-day simple moving average of $25.91 and a 200 day simple moving average of $27.15. Moderna has a twelve month low of $23.15 and a twelve month high of $57.69. The stock has a market cap of $10.41 billion, a PE ratio of -3.54 and a beta of 2.01.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business had revenue of $142.00 million during the quarter, compared to analysts’ expectations of $116.26 million. During the same quarter last year, the company earned ($3.33) earnings per share. The firm’s revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS.

Institutional Trading of Moderna

Hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp increased its holdings in shares of Moderna by 1.8% during the first quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company’s stock worth $54,382,000 after buying an additional 34,034 shares in the last quarter. Wealthfront Advisers LLC increased its holdings in shares of Moderna by 143.3% during the first quarter. Wealthfront Advisers LLC now owns 31,018 shares of the company’s stock worth $879,000 after buying an additional 18,268 shares in the last quarter. FORA Capital LLC increased its holdings in shares of Moderna by 31.7% during the first quarter. FORA Capital LLC now owns 97,072 shares of the company’s stock worth $2,752,000 after buying an additional 23,344 shares in the last quarter. Jump Financial LLC increased its holdings in shares of Moderna by 5,590.0% during the first quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock worth $25,584,000 after buying an additional 886,567 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Moderna by 12.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock worth $74,557,000 after buying an additional 285,662 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.